SCHEMBL14067741

SCHEMBL14067741

CC(=O)OCCNC(=O)c1cc2ccccc2cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
HDAC3 O15379 2/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC2 Q92769 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
DRD3 P35462 11/20 0.49
HTR2A P28223 9/20 0.49
HTR1A P08908 7/20 0.49
HTR2C P28335 7/20 0.48
EGLN1 Q9GZT9 1/20 0.48
HPGD P15428 1/20 0.47
DRD2 P14416 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31016920 0.82 HDAC3 (0.65) HDAC3HDAC1HDAC2DRD3HTR2A
SCHEMBL4078388 0.82 KDM4E (0.56) ALDH1A1KDM4EHDAC3HDAC1HDAC2
SCHEMBL14875993 0.80 EGLN1 (0.57) ALDH1A1KDM4EHDAC3HDAC1HDAC2
SCHEMBL16307678 0.79 HDAC3 (0.57) HDAC3HDAC1HDAC2DRD3HTR2A
SCHEMBL27833508 0.78 HIF1A (0.64) MEN1KMT2ACYP1A2CYP3A4EGLN1
SCHEMBL5100085 0.78 EGLN1 (0.52) ALDH1A1HDAC3HDAC1HDAC2DRD3
SCHEMBL5926434 0.78 EGLN1 (0.67) HDAC3HDAC1HDAC2DRD3HTR2A
SCHEMBL445261 0.78 NPC1 (0.52) MEN1KMT2ASMN1; SMN2HDAC3HDAC1
SCHEMBL29078735 0.77 KMT2A (0.50) MEN1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL14067675 0.77 MEN1 (0.56) MEN1KMT2AALDH1A1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
WO-2007038772-A1 NOVEL DRUGS FOR DEMENTIA AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227806-A1 Novel Drugs for Dementia CTSS, PRSS1, CBS MEN1 2586/4885KMT2A 3879/4885ALDH1A1 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.